HeartBlast FX Ingredients & Research

1. Terminalia Arjuna (350 mg)

The EF-Focused Myocardial Support Anchor

Known in Ayurveda as the “Guardian of the Heart,” Terminalia arjuna has been used for over 2,000 years in traditional cardiovascular care.

Modern clinical research has evaluated arjuna for measurable cardiac performance markers — including Left Ventricular Ejection Fraction (LVEF).

Key published findings include:

A 2022 randomized, double-blind, placebo-controlled trial showed a +6.3% improvement in LVEF over 8 weeks versus placebo.
A 2024 randomized controlled add-on trial in coronary artery disease patients reported improvements in EF and functional capacity.
Earlier controlled trials in chronic heart failure populations demonstrated improvements in ventricular performance and clinical symptoms.

Some trials show stronger EF movement in lower baseline EF ranges. Others show stabilization rather than large increases — reinforcing that botanical support works best as adjunctive, structured reinforcement, not as a pharmaceutical replacement.

Arjuna contains bioactive compounds including:

Arjunolic acid
Flavonoids
Tannins
Saponins

These compounds have been studied for their role in:

Supporting myocardial contractile efficiency
Supporting coronary blood flow
Enhancing myocardial oxygen utilization
Providing antioxidant protection to cardiac tissue

Standardized for arjunolic acid to support consistent potency.

Arjuna was selected because EF reflects pump strength — and pump strength depends on the heart muscle.

2. Hawthorn Berry Extract (200 mg)

Circulation & Rhythm Support

Derived from Crataegus species, Hawthorn has been extensively studied in mild-to-moderate chronic heart failure populations.

Clinical findings across major trials and reviews show:

Modest but statistically significant improvements in LVEF in certain CHF populations
Improvements in pressure-heart rate product
Improved vascular tone and endothelial function
Subgroup reductions in sudden cardiac death in long-term trials

Hawthorn contains:

Oligomeric proanthocyanidins (OPCs)
Flavonoids
Hyperoside
Vitexin

These compounds are associated with:

Supporting coronary circulation
Supporting ventricular efficiency
Supporting rhythm stability
Supporting vascular flexibility

Standardized to 1.8% vitexin for targeted cardiovascular relevance.

Hawthorn strengthens the delivery system — helping support oxygenated blood flow and steady rhythm patterns.

3. Astragalus Root Extract (200 mg, 10:1)

Cellular Resilience & Ventricular Remodeling Support

Astragalus membranaceus is a foundational herb in Traditional Chinese Medicine and has become one of the most studied botanicals in heart failure adjunct research.

Recent 2024 meta-analyses report:

A mean +5.82% increase in LVEF in HFrEF populations when combined with standard therapy
A mean +4.56% increase in LVEF in HFmrEF populations
Improvements in ventricular dimensions and NT-proBNP markers

Astragalus contains:

Astragalosides
Polysaccharides
Flavonoids

These constituents have been studied for their role in:

Supporting cellular ATP production
Supporting myocardial energy metabolism
Supporting vascular relaxation
Supporting structural remodeling processes

10:1 extract — equivalent to 2,000 mg raw herb per capsule equivalent (400 mg daily raw equivalent per serving depending on standardization structure; adjust to exact spec if needed).

Astragalus was selected to support the cellular environment in which the heart must function.

Research & Clinical Studies

1. Terminalia Arjuna

Here are the 4 updated studies on Terminalia arjuna and Ejection Fraction (EF), including direct links to each source:

Srivastava S et al. (2022)
Effect of E‑OJ‑01 (Oxyjun™) on Left Ventricular Ejection Fraction and Myocardial Oxygen Consumption: A Randomized, Double‑Blind, Placebo‑Controlled Study.
Published in Nutritional Journal. Demonstrated a +6.3% improvement in LVEF over 8 weeks vs. placebo.

https://pubmed.ncbi.nlm.nih.gov/36349244

Maulik SK et al. (2016)
Clinical efficacy of water extract of stem bark of Terminalia arjuna in chronic heart failure patients.
Published in Phytomedicine. Found no significant change in LVEF over 12 weeks.
https://www.sciencedirect.com/science/article/abs/pii/S0944711316000489
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9637339

Kuchewar V et al. (2024)
A Randomized Controlled Clinical Study to Evaluate the Effect of Terminalia Arjuna Add-On Medication on Cardiac Function in Coronary Artery Disease.
Found improvements in EF, 6-minute walk test, and lipid profile.
https://www.researchgate.net/publication/385775920
https://www.nutritionaloutlook.com/view/arjuna-bark-extract-oxyjun-supports-left-ventricle-ejection-fraction-says-recent-study

Bharani A et al. (1995)
Efficacy of Terminalia arjuna in chronic heart failure: a double-blind, placebo-controlled study.
Published in Journal of the Association of Physicians of India. Found improvements in clinical symptoms and likely EF in severe CHF.
https://www.sciencedirect.com/science/article/pii/016752739502320V

2. Hawthorn (Crataegus oxyacantha)

Here are four key studies on Hawthorn extract (Crataegus) focusing on left ventricular ejection fraction (LVEF) and cardiac function, complete with links and summaries:

HERB‑CHF Trial (2009)
A randomized, double-blind, placebo-controlled study in 120 NYHA class II–III heart failure patients (LVEF ≤40%) over 6 months. The hawthorn group (450 mg twice daily) showed a modest but statistically significant increase in LVEF (P=0.04), though no improvement in exercise capacity or symptoms ScienceDirect+15PubMed+15ClinicalTrials.gov+15.
Herb-CHF Full Text PDF

SPICE Trial – WS 1442 Extract (2008)
A large-scale trial (n=2681, NYHA II–III, LVEF ≤35%) using 900 mg/day of WS 1442 over 24 months. There was no significant difference in primary outcomes, but a subgroup with LVEF ≥25% experienced a 39.7% reduction in sudden cardiac death Deep Blue Repositories MDPI+9PubMed+9SpringerLink+9.
SPICE Trial Summary

HFpEF Exploratory Study – WS 1442 (2014)
In 140 HFpEF patients (NYHA II), eight weeks of aerobic training plus WS 1442 showed tendencies toward improved LVEF, better 2 km walking time (–12.7% vs –8.4%, P=0.019), and enhanced cardiac oxygen utilization Nature+5PubMed+5PubMed+5 CEEM Journal+14MDPI+14SpringerLink+14.
Trial DOI: 10.3390/sports2030059

Cochrane and Review Findings (2005‑2018)
Systematic reviews note that hawthorn extracts (LI 132, WS 1442) significantly improve LVEF, pressure–heart rate product, and exercise tolerance in mild-to-moderate CHF patients. However, no mortality benefit is established MDPI+1ResearchGate+1 Nature+3SpringerLink+3AAFP+3.
AAFP Overview (2005)

3. Astragalus membranaceus

Here are four key studies on Astragalus membranaceus focusing on ejection fraction (EF) and left ventricular function, complete with summaries and direct links:

Xu Han et al. (2024)
Effect of Astragalus membranaceus on left ventricular remodeling in HFrEF: systematic review & meta-analysis
Frontiers in Pharmacology – 19 RCTs (n=1,565) showed that Astragalus, combined with standard therapy, increased LVEF by a mean of 5.82% (95% CI: 4.61–7.03, p<0.00001), and significantly reduced left ventricular end-diastolic diameter (LVEDD) and systolic diameter (LVESD) Wikipedia+14PMC+14Frontiers+14 PubMed+1Frontiers+1.
https://pubmed.ncbi.nlm.nih.gov/38283626

Han X. et al. (2024)
Effect of astragalus injection on left ventricular remodeling in HFmrEF: systematic review & meta-analysis
Frontiers in Cardiovascular Medicine – 10 RCTs (n=995 HFmrEF patients) found a 4.56% mean increase in LVEF (95% CI: 3.68–5.44, p<0.00001), improvements in ventricular volumes, NT-proBNP, and clinical efficacy PubMed Frontiers.
https://doi.org/10.3389/fcvm.2024.1374114

Yang WJ et al. (2011)
Clinical effect of Astragalus granule on chronic heart failure
A 30-day RCT in 90 CHF patients testing three dosage levels (2.25g, 4.5g, 7.5g twice daily) found LVEF increases to ~59–62% in medium/high-dose groups vs. ~51% in low-dose (P<0.01) Frontiers+1PubMed+1 Wikipedia+5SpringerLink+5Frontiers+5.
https://doi.org/10.1007/s11655-011-0647-9

Xu Qiyao et al. (2024)
Combination decoction of Astragalus mongholicus & Salvia miltiorrhiza improves pressure-overload HF
Preclinical rat model (pressure-overload HF) showed that the decoction significantly prevented LVEF decline and improved cardiac function, likely via inhibition of ferroptosis pathways SpringerLink Frontiers+1Wikipedia+1.
https://doi.org/10.3389/fphar.2024.1447546

These studies demonstrate real-world and laboratory results supporting HeartBlast FX™'s formula. Always consult your healthcare provider for personal recommendations.

Start Supporting Your Heart Today

These statements have not been evaluated by the Food and Drug Administration (FDA). This product is not intended to diagnose, treat, cure, or prevent any disease. The information provided on this website or by this company is for educational purposes only and is not intended as a substitute for advice from your physician or other health care professional. You should not use the information on this website for diagnosis or treatment of any health problem or for prescription of any medication or other treatment. Always consult with a healthcare professional before starting any diet, exercise or supplementation program, before taking any medication, or if you suspect you might have a health problem.

HeartBlast FX™ is a dietary supplement and should be used only as directed on the label. Individual results may vary. The testimonials and statements on this page are not intended to guarantee that anyone will achieve the same or similar results. This site does not provide medical advice, diagnosis, or treatment.

The 3-Herb Cardiovascular Core

1. Terminalia Arjuna (350 mg)

2. Hawthorn Berry Extract (200 mg)

3. Astragalus Root Extract (200 mg, 10:1)

Why Only These Three?

Clinical Integrity Statement

Clinical Evidence Snapshot

Research & Clinical Studies

1. Terminalia Arjuna

2. Hawthorn (Crataegus oxyacantha)

3. Astragalus membranaceus

The 3-Herb Cardiovascular Core

1. Terminalia Arjuna (350 mg)

2. Hawthorn Berry Extract (200 mg)

3. Astragalus Root Extract (200 mg, 10:1)

Why Only These Three?

Clinical Integrity Statement

Clinical Evidence Snapshot

Research & Clinical Studies

1. Terminalia Arjuna

2. Hawthorn (Crataegus oxyacantha)

3. Astragalus membranaceus

This website uses cookies.